Awards Kwasi Adu-Berchie Named 2024 STAT WunderkindWyss Institute | November 1, 2024The Wyss Institute is thrilled to announce that Kwasi Adu-Berchie, Ph.D., a member of the…karnottNovember 1, 2024 Read More
Awards HMS Researcher Wins NIH Director’s Transformative Research AwardHarvard Medical School | October 31, 2024Ryan Flynn, assistant professor of stem cell and regenerative biology in the Blavatnik Institute at…karnottOctober 31, 2024 Read More
Publications of the Week AKT and EZH2 Inhibitors Kill TNBCs by Hijacking Mechanisms of InvolutionSchade, A., et al. | October 31, 2024Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest…karnottOctober 31, 2024 Read More
Local News Implantable Microparticles Can Deliver Two Cancer Therapies at OnceMIT News | October 31, 2024Patients with late-stage cancer often have to endure multiple rounds of different types of treatment,…karnottOctober 31, 2024 Read More
Local News Brain Pathways That Control Dopamine Release May Influence Motor ControlMIT News | October 30, 2024Within the human brain, movement is coordinated by a brain region called the striatum, which…karnottOctober 30, 2024 Read More
Local News New Diagnostic Approach for Bacterial Infections Shows Promise in the ClinicThe Broad Institute | October 30, 2024For patients with bacterial infections, the sooner they are treated with the appropriate antibiotics, the…karnottOctober 30, 2024 Read More
Local News First-of-Their-Kind Findings Turn Conventional Wisdom About Diffuse Hemispheric Glioma on Its HeadBoston Children's Hospital | October 29, 2024Diffuse hemispheric glioma, H3G34-mutant (DHG-H3G34) is a type of high-grade glioma that typically affects adolescents…karnottOctober 29, 2024 Read More
Local News Editas Prioritizes In Vivo Gene Therapies, Looks to Partner Reni-CelFierce Biotech | October 29, 2024Editas Medicine is pushing its in vivo gene therapy strategy to the top of its…karnottOctober 29, 2024 Read More
Local News Rectify Pharma Announces Positive Functional Modulator RTY-694 As Development Candidate for Primary Sclerosing CholangitisRectify Pharma | October 28, 2024Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics…karnottOctober 28, 2024 Read More
Awards Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of MedicineDana-Farber Cancer Institute | October 28, 2024David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been…karnottOctober 28, 2024 Read More